TRIAVIL 4-50
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRIAVIL 4-50 (TRIAVIL 4-50).
Amitriptyline is a tricyclic antidepressant that inhibits reuptake of serotonin and norepinephrine. Perphenazine is a typical antipsychotic that blocks dopamine D2 receptors.
| Metabolism | Amitriptyline is metabolized by CYP2D6, CYP2C19, and CYP3A4. Perphenazine is metabolized by CYP2D6 and CYP3A4. |
| Excretion | Renal: 50-60% as metabolites (amitriptyline and perphenazine), <5% unchanged; fecal: 20-30% (primarily perphenazine metabolites); biliary: minor route for perphenazine. |
| Half-life | Amitriptyline: 15-40 hours (mean 20-30 hours); perphenazine: 9-12 hours; clinical context: steady-state achieved within 5-7 days, dosing adjustments needed in hepatic impairment. |
| Protein binding | Amitriptyline: 90-95% bound to albumin and alpha-1-acid glycoprotein; perphenazine: 90-97% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Amitriptyline: 10-20 L/kg (widespread tissue distribution, high Vd indicates extensive extravascular binding); perphenazine: 10-20 L/kg (similar distribution pattern). |
| Bioavailability | Oral: amitriptyline 30-60% (first-pass metabolism, variability due to CYP2C19 and CYP2D6); perphenazine 20-40% (extensive first-pass metabolism). |
| Onset of Action | Oral: antidepressant effects of amitriptyline 2-4 weeks; antipsychotic effects of perphenazine 1-2 weeks; anxiolytic effects may occur within a few days. |
| Duration of Action | Amitriptyline: 24-48 hours (single dose), extended with repeated dosing; perphenazine: 12-24 hours; clinical notes: dosing usually 2-4 times daily; therapeutic effects persist after discontinuation due to slow elimination. |
| Molecular Weight | Amitriptyline HCl: 313.87 Da; Perphenazine: 403.97 Da |
One tablet (4 mg perphenazine / 50 mg amitriptyline) orally three times daily to four times daily. Maximum: 8 tablets per day.
| Dosage form | TABLET |
| Renal impairment | No specific dosing adjustment recommended; use caution in severe renal impairment (CrCl <10 mL/min) due to possible accumulation of amitriptyline metabolites. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Contraindicated due to risk of hepatotoxicity and central nervous system effects. |
| Pediatric use | Not recommended for children under 12 years. For adolescents (12-18 years): 1/2 to 1 tablet (2-4 mg perphenazine/25-50 mg amitriptyline) twice daily, titrate slowly. Maximum: 6 tablets per day. |
| Geriatric use | Initiate with 1/2 tablet (2 mg perphenazine/25 mg amitriptyline) once or twice daily; increase gradually. Maximum: 4 tablets per day due to increased sensitivity to anticholinergic, sedative, and cardiovascular effects. |
| 1st trimester | Avoid: Increased risk of congenital malformations (neural tube defects, cardiovascular) from amitriptyline; perphenazine may cause extrapyramidal effects. First-trimester exposure associated with MCMs. |
| 2nd trimester | Consider risk/benefit: Both components cross placenta; potential for maternal sedation and neonatal withdrawal/jitteriness. |
| 3rd trimester | Caution: Risk of neonatal withdrawal (lethargy, irritability, respiratory depression), anticholinergic effects, and extrapyramidal signs; avoid during delivery. |
Clinical note
Comprehensive clinical and safety monograph for TRIAVIL 4-50 (TRIAVIL 4-50).
| Placental transfer | Both drugs cross the placenta. Amitriptyline and perphenazine are lipophilic and readily transferred. Cord-to-maternal plasma ratios: amitriptyline ~0.5-1.0, perphenazine unknown but expected similar. |
| Breastfeeding | Both amitriptyline and perphenazine are excreted into breast milk. Low relative infant dose (about 1-2% of maternal weight-adjusted dose for amitriptyline). Monitor infant for sedation, poor feeding, and extrapyramidal effects. Use lowest effective dose; consider alternative if infant is premature or has hepatic impairment. |
■ FDA Black Box Warning
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
| Serious Effects |
Concurrent use of MAOIs (within 14 days)Recent myocardial infarctionClostridioides difficile infection (due to antipsychotic use? Not standard; but avoid in patients with QTc prolongation, history of seizures, narrow-angle glaucoma, urinary retention, bone marrow suppression, severe hepatic impairment, blood dyscrasias, CNS depression, coma.
| Precautions | May cause anticholinergic effects, sedation, orthostatic hypotension, QTc prolongation, extrapyramidal symptoms, neuroleptic malignant syndrome, tardive dyskinesia, and serotonin syndrome. |
| Food/Dietary | Avoid alcohol. Grapefruit juice may increase amitriptyline levels; limit or avoid consumption. High-tyramine foods (aged cheese, cured meats, soy products) can interact, especially when used with MAOIs, but risk is lower with this combination. Maintain adequate hydration and fiber to prevent constipation. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Increased risk of congenital malformations (neural tube defects, cardiovascular anomalies) with combination containing amitriptyline and perphenazine. Second and third trimesters: Risk of neonatal withdrawal (irritability, feeding difficulties) and extrapyramidal symptoms. Perphenazine may cause fetal neurobehavioral effects. Both components cross placenta. |
| Fetal Monitoring | Maternal: Serum levels of amitriptyline (if available), ECG for QT prolongation, liver and renal function, extrapyramidal symptoms, sedation. Fetal/neonatal: Ultrasound for congenital anomalies, neonatal monitoring for withdrawal, extrapyramidal signs, and cardiac function. |
| Fertility Effects | Both components may impair fertility. Amitriptyline can elevate prolactin levels, potentially causing menstrual irregularities and galactorrhea. Perphenazine is a potent dopamine antagonist, leading to hyperprolactinemia, anovulation, and reduced libido. Effects are reversible upon discontinuation. |
| Clinical Pearls | Triavil 4-50 contains 4 mg of perphenazine and 50 mg of amitriptyline. Use cautiously in elderly due to anticholinergic effects, sedation, and orthostatic hypotension. Avoid use in patients with recent MI, narrow-angle glaucoma, or MAOI use within 14 days. Monitor for extrapyramidal symptoms, tardive dyskinesia, and serotonin syndrome. Combine with other CNS depressants increases sedation. |
| Patient Advice | Take exactly as prescribed; do not stop abruptly. · May cause drowsiness; avoid driving or operating heavy machinery until effects are known. · Rise slowly from sitting or lying to prevent dizziness. · Avoid alcohol and other CNS depressants. · Report any muscle stiffness, tremors, or involuntary movements immediately. · Notify healthcare provider if you experience blurred vision, dry mouth, or difficulty urinating. · Store at room temperature away from moisture and heat. |